Toward Personalized Heart Failure Management: Integrating Biomarkers and Multimodal Monitoring Strategies

This new review examines the potential use of biomarkers in complex heart failure therapy and substantiates the feasibility of incorporating them into multimodal monitoring systems to create a more personalized and dynamic heart failure treatment model.

While natriuretic peptides remain the cornerstone of biomarker-based prognostication, emerging biomarkers reflecting diverse pathophysiological processes, such as myocardial stress, fibrosis, and inflammation, offer potential for enhanced risk stratification, particularly when used in serial multimarker panels. Despite their prognostic value, biomarkers are not yet routinely employed in guided therapy. Additionally with the increasing availability hemodynamic remote monitoring strategies and devices, we could learn more about pathophysiological processes, multi-biomarker panels and their relation to congestion and risks for progression of HF which can help to further refine biomarker-guided therapy.

 

https://link.springer.com/article/10.1007/s11897-026-00742-3

Scientific news

  • Engineered blood clots stop bleeding in seconds The blood in the vascular system of the body supports vital functions, but when it leaves the body, it must quickly form a strong protective barrier — a clot that prevents death. However, because natural blood clots are known to form very slowly, heavy bleeding from accidents, battlefield injuries, and surgical complications leads to many potentially preventable deaths. In an article for the journal Nature, Jiang et al. They talked about the achievements of bioengineering that solve this problem by fundamentally changing the structure of blood clots.
  • Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience Researchers conducted an international retrospective study including patients over 18 years of age from 33 centers with transposition of the great arteries (TGA) after atrial switch surgery and congenitally corrected TGA.
  • Cardiovascular disease in Sickle cell: mechanisms, diagnostics and therapeutic advances Cardiovascular complications are increasingly recognized as a major cause of morbidity and early mortality in patients with sickle cell disease, yet they remain underdiagnosed and underestimated. In a new review, the authors summarize current knowledge on a wide range of cardiovascular manifestations, including myocardial dysfunction, pulmonary hypertension, cardiac iron overload, arrhythmia, myocardial infarction, stroke, and sudden death, with an emphasis on their unique pathophysiological mechanisms in Wolf-Hirschhorn syndrome.
  • Parsimonious machine learning model to predict 1-year mortality and procedural futility after transcatheter aortic valve replacement Current risk assessment scores are insufficiently accurate in predicting long-term mortality after transcatheter aortic valve replacement, limiting their usefulness for decision-making regarding the feasibility of the procedure. The researchers aimed to develop and test a machine learning model on external data using only preoperative variables to predict all-cause mortality within one year.
  • Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy Population-based studies of congenital heart defects (CHDs) often include only children who have undergone cardiac surgery, leading to an underestimation of the number of cases that do not require intervention. In a new study, the authors analyzed the outcomes of all identified cases of structural CHDs in England from prenatal to one year of age.

Partners

Video resource

Channel "Cardioprogress"

Follow us

Top.Mail.Ru